A Phase 2 interventional study of PF-06651600 and Placebo in Alopecia Areata, sponsored by Pfizer. Terminated at 38 sites in 4 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Pfizer · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.
Among the 17 studies in Alopecia Areata by Pfizer, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 2, and was the 4th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Pfizer · Sites in United States, China, Czechia and 6 more countries
Ages 6–14
Pfizer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in United States, Canada, China and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2016; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 175 across the 10 interventional studies, 375 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Alopecia Areata by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alopecia Areata by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ritlecitinib 200 milligram (mg) once per day (QD) (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. At Month 9, participants assigned to this treatment arm will also receive 3 tablets of placebo for 4 weeks to maintain the blind with the other arm. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.
Drug: PF-06651600
matching comparator: placebo QD (4 tablets x 4 weeks then 1 tablet x 8 months) then ritlecitinib 200 mg QD (four 50 mg tablets) for 4 weeks then ritlecitinib 50 mg tablet QD through month 24. After month 24, participants switch to 50 mg capsules, 1 QD, up to month 60.
Drug: Placebo
50 mg tablet, dosed as 200 mg QD or 50 mg QD 50 mg capsule, dosed as 50 mg QD
Also known as: ritlecitinib
tablet, dosed as 4 tablets QD or 1 tablet QD
Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9
BAEP interwave I-V latency (in milliseconds) was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9
BAEP interwave I-V latency was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 6 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Months 9E and 15E (Month 9/15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-controlled Phase.
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 6 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 9E and 15E (Month 9/15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-controlled Phase.
Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9
The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings. IENF was assessed at Day 1 and Month 9. Participants who had entered the Active Therapy Extension Phase at Month 6 had a skin punch biopsy taken at Month 6 for IENF assessments instead of at Month 9. The skin biopsy was collected before the start of Active Therapy Extension Phase.
Time frame: Baseline, Month 9 (Month 6 for the 2 participants who entered the Active Therapy Extension Phase at Month 6). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E
The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings.
Time frame: Baseline, Month 15E (Month 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Change From Baseline in Intraepidermal Nerve Fiber Density (IENFD) in Skin Punch Biopsies at Month 9
IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.
Time frame: Baseline, Month 9 (Month 6 for the 2 participants who entered the Active Therapy Extension Phase at Month 6). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Change From Baseline in IENFD in Skin Punch Biopsies at Month 15E
IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.
Time frame: Baseline, Month 15E (Month 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 6 and Month 9
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 6 and Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Right Side at Month 9E and 15E
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 9E and 15E (Month 9 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 6 and Month 9
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 6 and Month 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in Amplitude of Wave V on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9E and 15E
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
Time frame: Baseline, Month 9E and 15E (Month 9 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase.
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side up to Month 9
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. At Month 9, 1 participant in 200/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. The event was unilateral and showed fluctuations in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6.
Time frame: Baseline, Month 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Right Side at Baseline, Month 3E, 6E, 9E and 15E
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.
Time frame: Baseline, Month 3E, 6E, 9E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side up to Month 9
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level.
Time frame: Baseline, Month 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Number of Participants With Absence of Wave V on BAEP at Stimulus Intensities Ranging From 80 dB to 40 dB From Left Side at Baseline, Month 3E, 6E, 9E and 15E
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.
Time frame: Baseline, Month 3E, 6E, 9E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of serious adverse event (SAE). An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.
Time frame: Approximately 16 months
Number of Participants Who Discontinued From Study Due to Adverse Event (AEs)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.
Time frame: Approximately 16 months
Number of Participants Who Discontinued Study Drug Due to AE and Continued Study
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This Outcome Measures presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.
Time frame: Approximately 16 months
Number of Participants With Temporary Drug Discontinuation Due to AEs
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.
Time frame: Approximately 16 months
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.
Time frame: Approximately 16 months
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values
Safety laboratory assessments included the categories of Hematology, Chemistry, Urinalysis and other tests. The clinical significance was determined by the investigator.
Time frame: Approximately 16 months
Change From Baseline in Overall Severity of Alopecia Tool (SALT) Scores up to Month 9
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
Time frame: Baseline, Months 3, 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in Overall SALT Scores at Month 3E, 6E, 9E, 12E and 15E
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
Time frame: Baseline, Month 3E, 6E, 9E, 12E and 15E (Month 3, 6, 9, 12 and 15 in the Active Therapy Extension Phase). Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase.
Change From Baseline in Alopecia Areata - Severity of Alopecia Tool (AA-SALT) Score up to Month 9
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score in Placebo-Controlled Phase = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
Time frame: Baseline, Months 3, 6 and 9 (Baseline was defined as the last non-missing measurement obtained before the first dose in the placebo-controlled phase)
Change From Baseline in AA-SALT Score at Month 3E, 6E, 9E, 12E and 15E
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
Time frame: Baseline, Month 3E, 6E, 9E, 12E and 15E (Baseline was defined as the last non-missing measurement obtained before the first dose in the Placebo-Controlled Phase)
Number of Participants With Patient's Global Impression of Change (PGI-C) Response up to Month 9
The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.
Time frame: Months 1, 3, 6 and 9
Number of Participants With PGI-C Response at 3E, 6E, 9E, 12E and 15E
The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.
Time frame: Month 3E, 6E, 9E, 12E and 15E
Number of Participants With TEAEs and TESAEs: Extension Phase (TP3)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of SAE. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.
Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Number of Participants Who Discontinued From Study Due to AEs: Extension Phase (TP3)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.
Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Number of Participants Who Discontinued Study Drug Due to AE and Continued Study: Extension Phase (TP3)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This outcome measure presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.
Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Number of Participants With Temporary Drug Discontinuation Due to AEs: Extension Phase (TP3)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.
Time frame: From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months)
Number of Participants With Clinically Significant Abnormalities in Vital Signs: Extension Phase (TP3)
Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants were refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.
Time frame: From screening up to 28 days follow up after last dose of study treatment (maximum up to 19 months)
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values: Extension Phase (TP3)
Safety laboratory assessments included the categories of hematology, chemistry, urinalysis and other tests. The clinical significance was determined by the investigator.
Time frame: From screening up to 28 days after last dose of study treatment (maximum up to 19 months)
| Milestone | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Ritlecitinib 50 mg QD |
|---|---|---|---|
| Started | 36 | 35 | 0 |
| Completed | 32 | 33 | 0 |
| Not completed | 4 | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Milestone | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Ritlecitinib 50 mg QD |
|---|---|---|---|
| Started | 32 | 33 | 0 |
| Completed | 21 | 24 | 0 |
| Not completed | 11 | 9 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 8 | 0 |
| Milestone | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Ritlecitinib 50 mg QD |
|---|---|---|---|
| Started | 0 | 0 | 45 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 45 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 32 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 |
| Withdrew: Approved drug available for indication | 0 | 0 | 7 |
BAEP interwave I-V latency (in milliseconds) was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
| Millisecond (ms) | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9 | 0.011 (-0.043 to 0.065) | -0.010 (-0.063 to 0.043) |
BAEP interwave I-V latency was the primary endpoint for this study. High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
| ms | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9 | 0.031 (-0.012 to 0.075) | 0.022 (-0.020 to 0.065) |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
| millisecond (ms) | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6 | -0.030 (-0.072 to 0.011) | -0.024 (-0.065 to 0.017) |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
| millisecond (ms) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Month 9E (Month 9 in the Active Therapy Extension Phase) | 0.010 ± 0.1233 | -0.033 ± 0.2448 |
| Month 15E (Month 15 in the Active Therapy Extension Phase) | 0.051 ± 0.1188 | 0.034 ± 0.2224 |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
| millisecond (ms) | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6 | 0.021 (-0.011 to 0.054) | -0.020 (-0.053 to 0.012) |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that latency were accurate. Central reading also ensured consistency in BAEP interpretation.
| millisecond (ms) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Month 9E (Month 9 in the Active Therapy Extension Phase) | 0.006 ± 0.1109 | 0.056 ± 0.1694 |
| Month 15E (Month 15 in the Active Therapy Extension Phase) | 0.024 ± 0.1044 | 0.017 ± 0.2339 |
The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings. IENF was assessed at Day 1 and Month 9. Participants who had entered the Active Therapy Extension Phase at Month 6 had a skin punch biopsy taken at Month 6 for IENF assessments instead of at Month 9. The skin biopsy was collected before the start of Active Therapy Extension Phase.
| Percentage of Nerve Fibers | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9 | 0.0 (-0.5 to 2.5) | 0.0 (-2.0 to 1.0) |
The endpoint "axonal dystrophy" referred to the percentage of IENF with axonal swellings. Axonal swellings were evaluated in peripheral skin punch biopsies from the distal part of lower extremities. Axonal swellings were counted by axon. Any IENF with single or multiple swellings was counted as a single event, ie, a single axon with axonal swellings. For each participant, data were reported as the percentage of IENF with any number of swellings.
| Percentage of Nerve Fibers | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E | 0 (-1.0 to 0) | 0 (-1.0 to 0) |
IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.
| fibers/mm | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Change From Baseline in Intraepidermal Nerve Fiber Density (IENFD) in Skin Punch Biopsies at Month 9 | -0.4 ± 3.90 | -0.2 ± 2.72 |
IENFD was evaluated in peripheral skin punch biopsies from the distal part of lower extremities. IENFD was measured by counting the number of fibers and fiber branches that independently crossed the dermal-epidermal barrier (basement membrane). Secondary branching was excluded from quantification and fragments were not counted. The length of the histology section was measured (mm) and the linear epidermal nerve fiber density was reported as number of intraepidermal nerve fibers/mm.
| fibers/mm | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Change From Baseline in IENFD in Skin Punch Biopsies at Month 15E | 0.2 ± 2.85 | -1.1 ± 3.51 |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
| Microvolts (μV) | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Month 6 | -0.031 (-0.063 to 0) | -0.017 (-0.048 to 0.015) |
| Month 9 | -0.051 (-0.085 to -0.018) | 0.008 (-0.025 to 0.041) |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
| μV | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Month 9E (Month 9 in the Active Therapy Extension Phase) | -0.052 ± 0.1109 | -0.025 ± 0.1649 |
| Month 15E (Month 15 in the Active Therapy Extension Phase) | -0.065 ± 0.1513 | -0.042 ± 0.1214 |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
| μV | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Month 6 | -0.047 (-0.082 to -0.013) | -0.019 (-0.053 to 0.015) |
| Month 9 | -0.045 (-0.082 to -0.008) | -0.049 (-0.085 to -0.012) |
High-intensity stimulation (80dB) was used. Participants had BAEP evaluations performed at the same evaluation center, by the same audiology professional using the same equipment, during the study. Audiology and BAEP evaluations were done on the same day, with audiology assessment first. If they could not be done on the same day, assessments had to be within 7 days of each other. A central reader was used for BAEP to confirm that locally read BAEP waves were labelled appropriately and at their peak so that amplitude data were accurate. Central reading also ensured consistency in BAEP interpretation.
| μV | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Month 9E | -0.058 ± 0.1209 | -0.025 ± 0.1307 |
| Month 15E | -0.047 ± 0.1314 | -0.023 ± 0.1217 |
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. At Month 9, 1 participant in 200/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. The event was unilateral and showed fluctuations in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6.
| Participants | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Baseline - 80 dB of normal hearing level (nHL) | 0 | 0 |
| Baseline - 70 dB nHL | 0 | 0 |
| Baseline - 60 dB nHL | 0 | 0 |
| Baseline - 50 dB nHL | 0 | 0 |
| Baseline - 40 dB nHL | 0 | 0 |
| Month 6 - 80 dB nHL | 0 | 0 |
| Month 6 - 70 dB nHL | 0 | 0 |
| Month 6 - 60 dB nHL | 0 | 0 |
| Month 6 - 50 dB nHL | 0 | 0 |
| Month 6 - 40 dB nHL | 0 | 0 |
| Month 9 - 80 dB nHL | 0 | 0 |
| Month 9 - 70 dB nHL | 0 | 0 |
| Month 9 - 60 dB nHL | 0 | 0 |
| Month 9 - 50 dB nHL | 0 | 0 |
| Month 9 - 40 dB nHL | 1 | 0 |
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.
| Participants | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Baseline - 80 dB nHL | 0 | 0 |
| Baseline - 70 dB nHL | 0 | 0 |
| Baseline - 60 dB nHL | 0 | 0 |
| Baseline - 50 dB nHL | 0 | 0 |
| Baseline - 40 dB nHL | 0 | 0 |
| Month 3E - 80 dB nHL | 0 | 0 |
| Month 3E - 70 dB nHL | 0 | 0 |
| Month 3E - 60 dB nHL | 0 | 0 |
| Month 3E - 50 dB nHL | 0 | 0 |
| Month 3E - 40 dB nHL | 0 | 0 |
| Month 6E - 80 dB nHL | 0 | 0 |
| Month 6E - 70 dB nHL | 0 | 0 |
| Month 6E - 60 dB nHL | 0 | 0 |
| Month 6E - 50 dB nHL | 0 | 0 |
| Month 6E - 40 dB nHL | 0 | 0 |
| Month 9E - 80 dB nHL | 0 | 0 |
| Month 9E - 70 dB nHL | 0 | 0 |
| Month 9E - 60 dB nHL | 0 | 0 |
| Month 9E - 50 dB nHL | 1 | 0 |
| Month 9E - 40 dB nHL | 1 | 0 |
| Month 15E - 80 dB nHL | 0 | 0 |
| Month 15E - 70 dB nHL | 0 | 0 |
| Month 15E - 60 dB nHL | 0 | 0 |
| Month 15E - 50 dB nHL | 0 | 0 |
| Month 15E - 40 dB nHL | 0 | 0 |
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level.
| Participants | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Baseline - 80 dB nHL | 0 | 0 |
| Baseline - 70 dB nHL | 0 | 0 |
| Baseline - 60 dB nHL | 0 | 0 |
| Baseline - 50 dB nHL | 0 | 0 |
| Baseline - 40 dB nHL | 0 | 0 |
| Month 6 - 80 dB nHL | 0 | 0 |
| Month 6 - 70 dB nHL | 0 | 0 |
| Month 6 - 60 dB nHL | 0 | 0 |
| Month 6 - 50 dB nHL | 0 | 0 |
| Month 6 - 40 dB nHL | 0 | 0 |
| Month 9 - 80 dB nHL | 0 | 0 |
| Month 9 - 70 dB nHL | 0 | 0 |
| Month 9 - 60 dB nHL | 0 | 0 |
| Month 9 - 50 dB nHL | 0 | 0 |
| Month 9 - 40 dB nHL | 0 | 0 |
Absence of wave V on BAEP at stimulus intensities ranging from 80dB to 40dB were summarized descriptively using number of participants by treatment group at each intensity level. All participants had Wave V on BAEP present at stimulus intensities ranging from 80 dB to 40 dB up to Month 15E except for 1 participant. At Month 9 (TP1), 1 participant in 200/50/50 mg had absence of Wave V on BAEP at a stimulus intensity of 40 dB on the right side. Fluctuations were seen in the presence or absence of Wave V at various intensities on repeat assessments starting at Month 6 on the right side.
| Participants | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Baseline - 80 dB nHL | 0 | 0 |
| Baseline - 70 dB nHL | 0 | 0 |
| Baseline - 60 dB nHL | 0 | 0 |
| Baseline - 50 dB nHL | 0 | 0 |
| Baseline - 40 dB nHL | 0 | 0 |
| Month 3E - 80 dB nHL | 0 | 0 |
| Month 3E - 70 dB nHL | 0 | 0 |
| Month 3E - 60 dB nHL | 0 | 0 |
| Month 3E - 50 dB nHL | 0 | 0 |
| Month 3E - 40 dB nHL | 0 | 0 |
| Month 6E - 80 dB nHL | 0 | 0 |
| Month 6E - 70 dB nHL | 0 | 0 |
| Month 6E - 60 dB nHL | 0 | 0 |
| Month 6E - 50 dB nHL | 0 | 0 |
| Month 6E - 40 dB nHL | 0 | 0 |
| Month 9E - 80 dB nHL | 0 | 0 |
| Month 9E - 70 dB nHL | 0 | 0 |
| Month 9E - 60 dB nHL | 0 | 0 |
| Month 9E - 50 dB nHL | 0 | 0 |
| Month 9E - 40 dB nHL | 0 | 0 |
| Month 15E - 80 dB nHL | 0 | 0 |
| Month 15E - 70 dB nHL | 0 | 0 |
| Month 15E - 60 dB nHL | 0 | 0 |
| Month 15E - 50 dB nHL | 0 | 0 |
| Month 15E - 40 dB nHL | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of serious adverse event (SAE). An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase |
|---|---|---|---|---|
| TEAE (All-Causality) | 29 | 22 | 3 | 3 |
| TEAE (Treatment-Related) | 9 | 5 | 0 | 1 |
| TESAE (All-Causality) | 0 | 1 | 1 | 0 |
| TESAE (Treatment-Related) | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase |
|---|---|---|---|---|
| Due to All-Causality AEs | 0 | 0 | 1 | 0 |
| Due to Treatment-Related AEs | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This Outcome Measures presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase |
|---|---|---|---|---|
| Due to All-Causality AEs | 1 | 0 | 0 | 0 |
| Due to Treatment-Related AEs | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase |
|---|---|---|---|---|
| Due to All-Causality AEs | 6 | 1 | 0 | 0 |
| Due to Treatment-Related AEs | 3 | 0 | 0 | 0 |
Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.
| Participants | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | 0 | 0 | 0 | 0 |
Safety laboratory assessments included the categories of Hematology, Chemistry, Urinalysis and other tests. The clinical significance was determined by the investigator.
| Participants | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values | 0 | 0 | 0 | 0 |
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
| Units on a scale | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Month 3 | -23.0 (-29.70 to -16.25) | -2.7 (-9.39 to 4.06) |
| Month 6 | -35.2 (-44.55 to -25.81) | -5.1 (-14.44 to 4.18) |
| Month 9 | -38.2 (-47.46 to -28.86) | -6.8 (-16.08 to 2.40) |
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. The overall SALT score included hair loss regardless of etiology (ie, scalp hair loss due to both non-AA and AA) and was collected at study visits. The Overall SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
| Units on a scale | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Baseline | 69.7 ± 31.56 | 69.6 ± 29.59 |
| Change at Month 3E | -41.7 ± 33.98 | -38.7 ± 33.49 |
| Change at Month 6E | -38.0 ± 29.88 | -43.4 ± 34.13 |
| Change at Month 9E | -38.7 ± 29.90 | -46.6 ± 34.14 |
| Change at Month 12E | -41.6 ± 29.67 | -48.9 ± 34.77 |
| Change at Month 15E | -44.6 ± 28.51 | -49.9 ± 34.40 |
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score in Placebo-Controlled Phase = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
| Units on a scale | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Month 3 | -23.0 (-29.70 to -16.25) | -2.7 (-9.39 to 4.06) |
| Month 6 | -35.2 (-44.55 to -25.81) | -5.1 (-14.44 to 4.18) |
| Month 9 | -38.2 (-47.46 to -28.87) | -6.8 (-16.08 to 2.40) |
SALT is a quantitative assessment of AA severity based on scalp terminal hair loss. AA-SALT is the amount of scalp hair loss due to AA. AA SALT score = overall SALT score - non-AA SALT score (The non-AA SALT score only took into account scalp hair loss other than that due to AA and was required to be assessed only at Month 9 \[or Month 6 for those who entered the Active Therapy Extension Phase at Month 6\] in Placebo-Controlled Phase). The AA-SALT Score ranged from 0 to 100%, with higher scores representing greater amount of hair loss.
| Units on a scale | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Baseline | 67.0 ± 33.52 | 69.5 ± 29.67 |
| Change at Month 3E | -41.7 ± 33.97 | -39.4 ± 32.89 |
| Change at Month 6E | -38.0 ± 29.87 | -44.2 ± 33.37 |
| Change at Month 9E | -38.7 ± 29.90 | -47.4 ± 33.36 |
| Change at Month 12E | -41.6 ± 29.70 | -49.7 ± 33.92 |
| Change at Month 15E | -44.8 ± 28.37 | -50.8 ± 33.49 |
The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.
| Participants | Ritlecitinib 200/50 mg QD | Placebo |
|---|---|---|
| Month 1 | 4 | 3 |
| Month 3 | 20 | 6 |
| Month 6 | 21 | 10 |
| Month 9 | 19 | 6 |
The PGI-C asked the participants to evaluate the improvement or worsening of their AA as compared to the start of the study using a single item, "Since the start of the study, my alopecia areata has: …". The participants selected one of seven responses ranging from "greatly improved" to "greatly worsened". This Outcome Measure presented the number of participants with PGI-C response which was defined as "greatly improved" or "moderately improved". Participants with missing PGI-C scores were considered as non-responders.
| Participants | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD |
|---|---|---|
| Month 3E | 22 | 22 |
| Month 6E | 16 | 20 |
| Month 9E | 20 | 18 |
| Month 12E | 17 | 18 |
| Month 15E | 17 | 18 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Seriousness of an AE was assessed under the criteria of SAE. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect, etc. Treatment-emergent events were with onset date occurring during the on-treatment period. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 50 mg QD |
|---|---|
| TEAEs | 19 |
| TESAEs | 1 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Participants who had an AE record that indicated that the AE caused the participant to be discontinued from the study. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 50 mg QD |
|---|---|
| Number of Participants Who Discontinued From Study Due to AEs: Extension Phase (TP3) | 1 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. This outcome measure presented the number of participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 50 mg QD |
|---|---|
| Number of Participants Who Discontinued Study Drug Due to AE and Continued Study: Extension Phase (TP3) | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with temporary drug discontinuation due to both all-causality and treatment-related AEs are presented below. Relatedness to study treatment was determined by the investigator.
| Participants | Ritlecitinib 50 mg QD |
|---|---|
| Number of Participants With Temporary Drug Discontinuation Due to AEs: Extension Phase (TP3) | 1 |
Oral, tympanic, or axillary temperature, pulse rate, respiratory rate, and blood pressure (BP) were assessed. BP and pulse measurements were assessed in a chair, back supported and arms bared (free of restrictions such as rolled-up sleeves, etc) and supported at heart level. Measurements were taken on the same arm at each visit (preferably non-dominant) with a completely automated device. Pulse rate was measured at approximately the same time as BP for a minimum of 30 seconds. BP and pulse measurements preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions (eg, television, cell phones). Participants were refrained from smoking or ingesting caffeine during the 30 minutes preceding the measurements. The clinical significance was determined by the investigator.
| Participants | Ritlecitinib 50 mg QD |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs: Extension Phase (TP3) | 0 |
Safety laboratory assessments included the categories of hematology, chemistry, urinalysis and other tests. The clinical significance was determined by the investigator.
| Participants | Ritlecitinib 50 mg QD |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values: Extension Phase (TP3) | 0 |
Collected over Placebo controlled phase (TP1) & Active therapy extension phase (TP2): 24 months, Extension phase (TP3): From first dose of treatment up to 28 days follow up after last dose of study treatment (Approximately 19 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | 0/36 (0%) | 0/36 (0%) | 23/36 (63.9%) |
| Placebo - Placebo-Controlled Phase | 0/35 (0%) | 1/35 (2.9%) | 17/35 (48.6%) |
| Ritlecitinib 50 mg QD - Active Therapy Extension Phase | 0/32 (0%) | 2/32 (6.3%) | 16/32 (50%) |
| Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase | 0/33 (0%) | 1/33 (3%) | 12/33 (36.4%) |
| Ritlecitinib 50 mg QD: Extension Phase | 0/45 (0%) | 1/45 (2.2%) | 10/45 (22.2%) |
| Event | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase | Ritlecitinib 50 mg QD: Extension Phase |
|---|---|---|---|---|---|
| Takayasu's arteritisVascular disorders | 0/36 | 0/35 | 1/32 | 0/33 | 0/45 |
| Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/36 | 0/35 | 1/32 | 0/33 | 0/45 |
| Chronic pigmented purpuraSkin and subcutaneous tissue disorders | 0/36 | 0/35 | 0/32 | 1/33 | 0/45 |
| Humerus fractureInjury, poisoning and procedural complications | 0/36 | 1/35 | 0/32 | 0/33 | 0/45 |
| Biliary colicHepatobiliary disorders | 0/36 | 0/35 | 0/32 | 0/33 | 1/45 |
| Event | Ritlecitinib 200/50 mg QD - Placebo-Controlled Phase | Placebo - Placebo-Controlled Phase | Ritlecitinib 50 mg QD - Active Therapy Extension Phase | Ritlecitinib 200/50 mg QD - Active Therapy Extension Phase | Ritlecitinib 50 mg QD: Extension Phase |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 3/36 | 3/35 | 5/32 | 6/33 | 1/45 |
| Acne pustularInfections and infestations | 4/36 | 0/35 | 0/32 | 0/33 | 0/45 |
| HeadacheNervous system disorders | 4/36 | 1/35 | 0/32 | 3/33 | 0/45 |
| NasopharyngitisInfections and infestations | 2/36 | 1/35 | 3/32 | 2/33 | 2/45 |
| ParaesthesiaNervous system disorders | 1/36 | 1/35 | 3/32 | 0/33 | 0/45 |
| NauseaGastrointestinal disorders | 1/36 | 3/35 | 0/32 | 0/33 | 0/45 |
| HypoaesthesiaNervous system disorders | 1/36 | 3/35 | 2/32 | 0/33 | 0/45 |
| DiarrhoeaGastrointestinal disorders | 3/36 | 0/35 | 0/32 | 0/33 | 1/45 |
| VomitingGastrointestinal disorders | 3/36 | 1/35 | 1/32 | 0/33 | 0/45 |
| DizzinessNervous system disorders | 3/36 | 1/35 | 0/32 | 0/33 | 0/45 |
Baseline analysis population included all participants taking at least 1 dose of study intervention.
| Age, Continuous(Years) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Total |
|---|---|---|---|
| Mean | 35.1 ± 9.64 | 34.2 ± 8.95 | 34.7 ± 9.25 |
| Sex: Female, Male(Participants) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Total |
|---|---|---|---|
| Female | 25 | 25 | 50 |
| Male | 11 | 10 | 21 |
| Race (NIH/OMB)(Participants) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 4 | 11 |
| White | 26 | 28 | 54 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Baseline Percentage of Nerve Fibers With Axonal Swelling(Percentage of Nerve Fibers) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Total |
|---|---|---|---|
| Mean | 1.8 ± 2.48 | 1.8 ± 2.07 | 1.8 ± 2.27 |
| Baseline Intraepidermal Nerve Fiber Density (IENFD)(fibers/mm) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Total |
|---|---|---|---|
| Mean | 10.2 ± 3.81 | 11.0 ± 3.95 | 10.6 ± 3.87 |
| Baseline Severity of Alopecia Tool (SALT) Scores for Non-AT/AU Participants(Units on a scale) | Ritlecitinib 200/50/50 mg QD | Placebo -> Ritlecitinib 200/50 mg QD | Total |
|---|---|---|---|
| Mean | 59.6 ± 30.31 | 53.7 ± 24.18 | 56.9 ± 27.55 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2020 to primary completion in Jan 2022, 15 months.
Results were first posted in Dec 2022, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600